🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join Leading Experts & COR2ED for Rapid Video Insights on Groundbreaking Data out of #ASCO25 LINK: buff.ly/He9wEAY a series of brief videos featuring Prof. Gerhardt Attard presenting late-breaking prostate cancer trial results from the AMPLITUDE study, Prof.

📣Highlights from ESMO Breast Cancer 2025 Satellite Symposium Medical experts discuss treatment strategies/sequencing after ET + CDK4/6i for ER+/HER2- metastatic #breastcancer 📺 Watch the video 🔗Download the slides: cor2ed.com/n-connect/prog… This programme has been sponsored

Don't miss the OncoAlert Newsletter: The Complete #ASCO2025 edition, released today!

Join Leading Experts & COR2ED for Rapid Video Insights on Groundbreaking Data out of #ASCO25 LINK: buff.ly/He9wEAY a series of brief videos featuring Prof. Gerhardt Attard presenting late-breaking prostate cancer trial results from the AMPLITUDE study, Prof.

Catch up on highlights from #ASCO25! Experts joined us at ASCO to share their insights on how the latest data could change clinical practice ➡️ Prof. Mark Socinski: #NSCLC (downloadable slides also available) ➡️ Dr AttardLab: #ProstateCancer ➡️ Dr Lizzy Smyth: #GastricCancer

Watch the full video series on rethinking HPP here 📹>> cor2ed.com/n-connect/prog… Recognising #hypophosphatasia (HPP) 🔍 At #EULAR2025, reconsider which of your patients may have HPP, as we ask: ➡️ How can you recognise rheumatic presentations of HPP? ➡️ What are common

Watch the full video series on rethinking HPP here >> cor2ed.com/n-connect/prog… The evolution of our understanding that led us to rethink #hypophosphatasia (HPP) While we come together at #EULAR2025, we invite you to watch a short video on understanding HPP Dr Chad Deal

We are heading to #EHA2025 in Milan tomorrow! We’re looking forward to hearing the latest advances in hematology and exploring how they can support healthcare professionals and patients around the world. If you’re attending, we’d be delighted to meet — feel free to reach out!

📣 Breast cancer podcast! 📣 Expert insights on the subgroup analyses from the phase 3 EMERALD trial by prior duration of ET + CDK4/6i & in clinical subgroups Watch the full video 📹 or listen to the audio on Spotify/Apple ⬇️ cor2ed.com/n-connect/prog… w/ Aditya Bardia, MD & Dr

Treatment strategies/sequencing after ET + CDK4/6i for ER+/HER2- metastatic #breastcancer ➡️Experts share highlights from #ESMO Breast Cancer 2025 Satellite Symposium Watch the video/download the slides: cor2ed.com/n-connect/prog… This programme has been sponsored by Menarini

Catch this ESMO Virtual Plenary 2025 update on the latest TROPION-Breast01 study with Prof. François-Clément Bidard & Dr Barbara Pistilli This study evaluates datopotamab deruxtecan (Dato-DXd) versus chemotherapy in previously treated, inoperable or metastatic HR+/HER2– breast

How is molecular classification transforming prognosis and personalising treatment in endometrial cancer? Find out here: cor2ed.com/obstetrics-gyn… #MedEd #Oncology #PrecisionMedicine #OBGYN This educational programme is sponsored by an Independent Educational Grant from Eisai

Watch the full video series on rethinking HPP here >> cor2ed.com/n-connect/prog… With a successful #EULAR2025 fresh in our minds, we are pleased to share a #MedEd video on recognising #hypophosphatasia (HPP) 🎓 HPP is ➡️ associated with impaired bone mineralisation, muscle

Watch the full video series on rethinking HPP here 📹>> cor2ed.com/n-connect/prog… Continue your learning after #EULAR2025 with this #MedEd video 🎓 ➡️ Despite being a lifelong metabolic condition, #hypophosphatasia (HPP) is often under recognised in patients & commonly